ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
Exxon Mobil’s XTO Energy Explores Sale of Eagle Ford Shale Assets in South Texas 
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
FCC Chairman Raises Competition Concerns Over Netflix–Warner Bros. Discovery Deal 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
Microsoft Restores Microsoft 365 Services After Widespread Outage 
Nintendo Stock Jumps as Switch 2 Becomes Best-Selling Console in the U.S. in 2025 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
SEC Drops Gemini Enforcement Case After Full Repayment to Earn Investors 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Goldman Sachs CEO David Solomon’s 2025 Pay Soars to $47 Million After Strong Deal-Making Year 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
Toyota Recalls 162,000 Tundra Vehicles in U.S. Over Multimedia Display Issue 
MORRISTOWN, N.J., May 08, 2017 -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) a specialty pharmaceutical company, announced today that the Company will report financial results for the first quarter ended March 31, 2017, after the market close on Monday, May 15, 2017. John Sedor, Chairman and Chief Executive Officer, and Graham Miao, President and Chief Financial Officer, will host a conference call to discuss the results.
| Date: | Monday, May 15 | ||
| Time: | 4:30 PM ET | ||
| Toll free (U.S.): | 888-504-7953 | ||
| International: | 719-457-2643 | ||
| Conference ID: | 4336660 | ||
| Webcast: | http://public.viavid.com/index.php?id=124373 |
About Pernix Therapeutics
Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company targets underserved therapeutic areas such as CNS, including neurology and psychiatry, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its Pernix sales force, uses contracted sales organizations to market its non-core, cough and cold products, and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc.
To learn more about Pernix Therapeutics, visit www.pernixtx.com.
CONTACT Investor Relations Matthew P. Duffy, 212-915-0685 LifeSci Advisors, LLC [email protected]
